These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30455719)

  • 1. Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action.
    Shardlow E; Mold M; Exley C
    Allergy Asthma Clin Immunol; 2018; 14():80. PubMed ID: 30455719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations.
    Mold M; Shardlow E; Exley C
    Sci Rep; 2016 Aug; 6():31578. PubMed ID: 27515230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice.
    Freiberger SN; Leuthard DS; Duda A; Contassot E; Thallmair M; Kündig TM; Johansen P
    Eur J Pharm Sci; 2018 Mar; 115():362-368. PubMed ID: 29410031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequestering of damage-associated molecular patterns (DAMPs): a possible mechanism affecting the immune-stimulating properties of aluminium adjuvants.
    Svensson A; Sandberg T; Siesjö P; Eriksson H
    Immunol Res; 2017 Dec; 65(6):1164-1175. PubMed ID: 29181774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aluminium adjuvants in vaccines - A way to modulate the immune response.
    Danielsson R; Eriksson H
    Semin Cell Dev Biol; 2021 Jul; 115():3-9. PubMed ID: 33423930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Aluminium Hydroxide Nanoparticles as an Efficient Adjuvant to Potentiate the Immune Response against
    Mbhele Z; Thwala L; Khoza T; Ramagoma F
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766149
    [No Abstract]   [Full Text] [Related]  

  • 7. Nanoalum adjuvanted vaccines: small details make a big difference.
    Raponi A; Brewer JM; Garside P; Laera D
    Semin Immunol; 2021 Aug; 56():101544. PubMed ID: 34895823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.
    Petrovsky N
    Drug Saf; 2015 Nov; 38(11):1059-74. PubMed ID: 26446142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminium based adjuvants and their effects on mitochondria and lysosomes of phagocytosing cells.
    Ohlsson L; Exley C; Darabi A; Sandén E; Siesjö P; Eriksson H
    J Inorg Biochem; 2013 Nov; 128():229-36. PubMed ID: 23992993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Stock Bottle to Vaccine: Elucidating the Particle Size Distributions of Aluminum Adjuvants Using Dynamic Light Scattering.
    Shardlow E; Mold M; Exley C
    Front Chem; 2016; 4():48. PubMed ID: 28119911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy.
    Exley C
    Allergy Asthma Clin Immunol; 2014 Jan; 10(1):4. PubMed ID: 24444186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a cell line-based in vitro assay for assessment of Diphtheria, Tetanus and acellular Pertussis (DTaP)-induced inflammasome activation.
    Vandebriel RJ; Stalpers CAL; Vermeulen JP; Remkes M; Schmelter M; Broere F; Hoefnagel MHN
    Vaccine; 2022 Sep; 40(38):5601-5607. PubMed ID: 35999078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical properties and adsorption state of aluminum adjuvants with different processes in vaccines.
    Bo C; Wei X; Wang X; Ji W; Yang H; Zhao Y; Wang H
    Heliyon; 2023 Aug; 9(8):e18800. PubMed ID: 37560692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aluminum as an adjuvant in vaccines and post-vaccine reactions].
    Fiejka M; Aleksandrowicz J
    Rocz Panstw Zakl Hig; 1993; 44(1):73-80. PubMed ID: 8235346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of aluminium-containing adjuvants.
    White JL; Hem SL
    Dev Biol (Basel); 2000; 103():217-28. PubMed ID: 11214239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence.
    Jefferson T; Rudin M; Di Pietrantonj C
    Lancet Infect Dis; 2004 Feb; 4(2):84-90. PubMed ID: 14871632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
    Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
    Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (How) do aluminium adjuvants work?
    Brewer JM
    Immunol Lett; 2006 Jan; 102(1):10-5. PubMed ID: 16188325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminium compounds for use in vaccines.
    Lindblad EB
    Immunol Cell Biol; 2004 Oct; 82(5):497-505. PubMed ID: 15479435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants.
    Reinke S; Thakur A; Gartlan C; Bezbradica JS; Milicic A
    Vaccines (Basel); 2020 Sep; 8(3):. PubMed ID: 32971761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.